Exchange: NASDAQ·Updated 04:06 AM EDT
TELO logo

TELOTelomir Pharmaceuticals Inc

$1.25
$0.00
(0.00%)
Pre-Market
Prev Close $1.25
Mkt Cap$88.03M
Vol14.00
News
all
press releases
EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study
Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.read more...
Benzinga
News Placeholder
More News
News Placeholder
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% - Here's What Happened...
MarketBeat
News Placeholder
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death
HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.
Stocktwits
News Placeholder
Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today
The company said that its experimental drug, Telomir-1, selectively kills aggressive triple-negative breast cancer cells by disrupting their iron-based energy systems.
Stocktwits
News Placeholder
Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains
The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging.
Stocktwits
<
...
1
>

Advertisement|Remove ads.